Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs). (4th May 2018)

• Record Type: Journal Article
• Authors: Du, Zuo; Wang, Guang; Cao, Yun-Feng; Hu, Cui-Min; Yang, Kun; Liu, Yong-Zhe; Zhang, Chun-Ze; Zhang, Wei-Hua; Zhu, Zhi-Tu; Sun, Hong-Zhi; Sun, Xiao-Yu; Hong, Mo; Fang, Zhong-Ze
• Is Part Of: Xenobiotica. Volume 48:Number 5(2018:May)
• Page Start: 452
• Page End: 458
• Publication Date: 2018-05-04
• Subjects: Drug–drug interaction -- everolimus -- enzyme inhibition -- UDP-glucuronosyltransferases; Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.1080/00498254.2017.1335917
• Languages: English
• ISSNs: 0049-8254

Abstract

Abstract: 1. Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) and has been clinically utilized to prevent the rejection of organ transplants. This study aims to determine the inhibition of everolimus on the activity of phase-II drug-metabolizing enzymes UDP-glucuronosyltransferases (UGTs). 2. The results showed that 100 μM of everolimus exerted more than 80% inhibition toward UGT1A1, UGT-1A3 and UGT-2B7. UGT1A3 and UGT2B7 were selected to elucidate the inhibition mechanism, and in silico docking showed that hydrogen bonds and hydrophobic interactions mainly contributed to the strong binding of everolimus toward the activity cavity of UGT1A3 and UGT2B7. Inhibition kinetic-type analysis using Lineweaver–Burk plot showed competitive inhibition toward all these UGT isoforms. The inhibition kinetic parameters ( K i ) were calculated to be 2.3, 0.07 and 4.4 μM for the inhibition of everolimus toward UGT1A1, UGT-1A3 and UGT-2B7, respectively. 3. In vitro – in vivo extrapolation ( IVIVE ) showed that [ I ]/ K i value was calculated to be 0.004, 0.14 and 0.002 for UGT1A1, UGT-1A3 and UGT-2B7, respectively. Therefore, high DDI potential existed between everolimus and clinical drugs mainly undergoing UGT1A3-catalyzed glucuronidation.